First Time Loading...

Kronos Bio Inc
NASDAQ:KRON

Watchlist Manager
Kronos Bio Inc Logo
Kronos Bio Inc
NASDAQ:KRON
Watchlist
Price: 1.03 USD
Updated: May 2, 2024

Intrinsic Value

KRON's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. [ Read More ]

The intrinsic value of one KRON stock under the Base Case scenario is 0.81 USD. Compared to the current market price of 1.03 USD, Kronos Bio Inc is Overvalued by 21%.

Key Points:
KRON Intrinsic Value
Base Case
0.81 USD
Overvaluation 21%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Kronos Bio Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling KRON stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Kronos Bio Inc

Provide an overview of the primary business activities
of Kronos Bio Inc.

What unique competitive advantages
does Kronos Bio Inc hold over its rivals?

What risks and challenges
does Kronos Bio Inc face in the near future?

Has there been any significant insider trading activity
in Kronos Bio Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Kronos Bio Inc.

Provide P/S
for Kronos Bio Inc.

Provide P/E
for Kronos Bio Inc.

Provide P/OCF
for Kronos Bio Inc.

Provide P/FCFE
for Kronos Bio Inc.

Provide P/B
for Kronos Bio Inc.

Provide EV/S
for Kronos Bio Inc.

Provide EV/GP
for Kronos Bio Inc.

Provide EV/EBITDA
for Kronos Bio Inc.

Provide EV/EBIT
for Kronos Bio Inc.

Provide EV/OCF
for Kronos Bio Inc.

Provide EV/FCFF
for Kronos Bio Inc.

Provide EV/IC
for Kronos Bio Inc.

Show me price targets
for Kronos Bio Inc made by professional analysts.

What are the Revenue projections
for Kronos Bio Inc?

How accurate were the past Revenue estimates
for Kronos Bio Inc?

What are the Net Income projections
for Kronos Bio Inc?

How accurate were the past Net Income estimates
for Kronos Bio Inc?

What are the EPS projections
for Kronos Bio Inc?

How accurate were the past EPS estimates
for Kronos Bio Inc?

What are the EBIT projections
for Kronos Bio Inc?

How accurate were the past EBIT estimates
for Kronos Bio Inc?

Compare the revenue forecasts
for Kronos Bio Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Kronos Bio Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Kronos Bio Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Kronos Bio Inc compared to its peers.

Compare the P/E ratios
of Kronos Bio Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Kronos Bio Inc with its peers.

Analyze the financial leverage
of Kronos Bio Inc compared to its main competitors.

Show all profitability ratios
for Kronos Bio Inc.

Provide ROE
for Kronos Bio Inc.

Provide ROA
for Kronos Bio Inc.

Provide ROIC
for Kronos Bio Inc.

Provide ROCE
for Kronos Bio Inc.

Provide Gross Margin
for Kronos Bio Inc.

Provide Operating Margin
for Kronos Bio Inc.

Provide Net Margin
for Kronos Bio Inc.

Provide FCF Margin
for Kronos Bio Inc.

Show all solvency ratios
for Kronos Bio Inc.

Provide D/E Ratio
for Kronos Bio Inc.

Provide D/A Ratio
for Kronos Bio Inc.

Provide Interest Coverage Ratio
for Kronos Bio Inc.

Provide Altman Z-Score Ratio
for Kronos Bio Inc.

Provide Quick Ratio
for Kronos Bio Inc.

Provide Current Ratio
for Kronos Bio Inc.

Provide Cash Ratio
for Kronos Bio Inc.

What is the historical Revenue growth
over the last 5 years for Kronos Bio Inc?

What is the historical Net Income growth
over the last 5 years for Kronos Bio Inc?

What is the current Free Cash Flow
of Kronos Bio Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Kronos Bio Inc.

Financials

Balance Sheet Decomposition
Kronos Bio Inc

Current Assets 178.8m
Cash & Short-Term Investments 173m
Other Current Assets 5.8m
Non-Current Assets 34.5m
Long-Term Investments 2m
PP&E 29.9m
Other Non-Current Assets 2.6m
Current Liabilities 24.7m
Accounts Payable 883k
Accrued Liabilities 13.8m
Other Current Liabilities 10m
Non-Current Liabilities 29.5m
Other Non-Current Liabilities 29.5m
Efficiency

Earnings Waterfall
Kronos Bio Inc

Revenue
6.3m USD
Operating Expenses
-125.2m USD
Operating Income
-118.9m USD
Other Expenses
6.3m USD
Net Income
-112.7m USD

Free Cash Flow Analysis
Kronos Bio Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

KRON Profitability Score
Profitability Due Diligence

Kronos Bio Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

15/100
Profitability
Score

Kronos Bio Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

KRON Solvency Score
Solvency Due Diligence

Kronos Bio Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
60/100
Solvency
Score

Kronos Bio Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KRON Price Targets Summary
Kronos Bio Inc

Wall Street analysts forecast KRON stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KRON is 4.34 USD with a low forecast of 2.53 USD and a high forecast of 6.3 USD.

Lowest
Price Target
2.53 USD
145% Upside
Average
Price Target
4.34 USD
321% Upside
Highest
Price Target
6.3 USD
512% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

KRON Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

KRON Price
Kronos Bio Inc

1M 1M
-19%
6M 6M
+29%
1Y 1Y
-36%
3Y 3Y
-96%
5Y 5Y
-96%
10Y 10Y
-96%
Annual Price Range
1.03
52w Low
0.75
52w High
2.25
Price Metrics
Average Annual Return -44.31%
Standard Deviation of Annual Returns 46.75%
Max Drawdown -98%
Shares Statistics
Market Capitalization 60.7m USD
Shares Outstanding 60 095 000
Percentage of Shares Shorted 1.42%

KRON Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Kronos Bio Inc Logo
Kronos Bio Inc

Country

United States of America

Industry

Biotechnology

Market Cap

60.7m USD

Dividend Yield

0%

Description

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. The company is headquartered in San Mateo, California and currently employs 96 full-time employees. The company went IPO on 2020-10-09. The firm is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).

Contact

CALIFORNIA
San Mateo
1300 S. El Camino Real, Suite 400
+12128717920.0
https://kronosbio.com/

IPO

2020-10-09

Employees

96

Officers

President, CEO & Director
Dr. Norbert W. Bischofberger Ph.D.
Co-Founder & Director
Mr. Joshua A. Kazam
Interim CFO & Principal Accounting Officer
Ms. Sandra A. Gardiner
Vice President of Corporate Development & Investor Relations
Dr. Margaux Bennett Ph.D.
Senior Vice President of Corporate Operations & Legal
Ms. Allison Frisbee J.D.
Senior Vice President of Research & Development
Dr. Charles Lin Ph.D.
Show More
Senior Vice President of Clinical Development
Dr. Elizabeth A. Olek D.O., M.P.H.
Senior Vice President of Drug Discovery & Pharmaceutical Development
Mr. Wes Trotter Ph.D.
Senior Vice President of Corporate Strategy & Portfolio Management
Ms. Rocio Martin Hoyos
Show Less

See Also

Discover More
What is the Intrinsic Value of one KRON stock?

The intrinsic value of one KRON stock under the Base Case scenario is 0.81 USD.

Is KRON stock undervalued or overvalued?

Compared to the current market price of 1.03 USD, Kronos Bio Inc is Overvalued by 21%.